Immunic, Inc.
IMUX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $80,046 | $83,215 | $71,255 | $61,115 |
| G&A Expenses | $18,006 | $16,008 | $15,263 | $13,300 |
| SG&A Expenses | $18,006 | $16,008 | $15,263 | $13,300 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $32,970 | $17,250 |
| Operating Expenses | $98,052 | $99,223 | $119,488 | $91,665 |
| Operating Income | -$98,052 | -$99,223 | -$119,488 | -$91,665 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,455 | $5,611 | -$919 | -$1,280 |
| Pre-Tax Income | -$100,507 | -$93,612 | -$120,407 | -$92,945 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$100,507 | -$93,612 | -$120,407 | -$92,945 |
| % Margin | – | – | – | – |
| EPS | -1 | -2.11 | -3.78 | -3.92 |
| % Growth | 52.6% | 44.2% | 3.6% | – |
| EPS Diluted | -1 | -2.11 | -3.78 | -3.92 |
| Weighted Avg Shares Out | 100,175 | 44,320 | 31,819 | 23,653 |
| Weighted Avg Shares Out Dil | 100,175 | 44,320 | 31,819 | 23,653 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,390 | $3,075 | $1,041 | $66 |
| Interest Expense | $0 | $0 | $1,041 | $0 |
| Depreciation & Amortization | $134 | $111 | $77 | $85 |
| EBITDA | -$97,918 | -$99,112 | -$86,441 | -$91,580 |
| % Margin | – | – | – | – |